Holen Sie sich die Stockscreener-App
58.07
0.19%
0.11
Handel nachbörslich:
58.00
-0.07
-0.12%
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
Will BioMarin Pharmaceutical Inc. Reverse From Oversold ConditionsJuly 2025 Snapshot & Fast Exit Strategy with Risk Control - classian.co.kr
BioMarin stock price target raised to $95 by Bernstein following Inozyme acquisition - Investing.com
2 Reasons to Watch BMRN and 1 to Stay Cautious - Yahoo Finance
Predicting the Next Rule Breaker Buyout - The Motley Fool
BioMarin (BMRN) Posts Strong Q2 Growth, Advances Rare Disease Research - MSN
BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Can BioMarin Pharmaceutical Inc. Overcome Bearish SentimentMarket Volume Summary & Long-Term Growth Plans - classian.co.kr
Trendlines Suggest BioMarin Pharmaceutical Inc. May Bottom Out Soon2025 Big Picture & High Conviction Buy Zone Alerts - kangso.co.kr
BioMarin Fights Back After NICE Blocks English Funding For £500K Batten Disease Drug - insights.citeline.com
Trapped Investors in BioMarin Pharmaceutical Inc. Await Breakout Signal2025 Retail Activity & Technical Entry and Exit Alerts - metal.it
U.S. Batten disease experts who lobbied B.C. to reinstate drug had relationships with company - Times Colonist
Evaluating BioMarin Pharmaceutical Inc. with trendline analysis2025 Performance Recap & AI Forecast Swing Trade Picks - Newser
Is BioMarin Pharmaceutical Inc. forming a bottoming baseMarket Performance Report & Verified Short-Term Trading Plans - Newser
BioMarin’s SWOT analysis: rare disease specialist’s stock faces competition, pipeline potential - Investing.com Nigeria
BioMarin’s SWOT analysis: rare disease specialist’s stock faces competition, pipeline potential By Investing.com - Investing.com South Africa
What machine learning models say about BioMarin Pharmaceutical Inc.2025 Support & Resistance & Advanced Technical Signal Analysis - Newser
Leerink Partners Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $105 - MSN
Azenta, LifeStance Health Group, BioMarin Pharmaceutical, AMN Healthcare Services, and ANI Pharmaceuticals Stocks Trade Up, What You Need To Know - Yahoo Finance
Azenta, LifeStance Health Group, BioMarin Pharmaceutical, AMN Healthcare Services, and ANI Pharmaceuticals Stocks Trade Up, What You Need To Know | FinancialContent - FinancialContent
Is BioMarin Pharmaceutical Inc. stock poised for growthJuly 2025 Catalysts & Risk Controlled Stock Pick Alerts - Newser
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - Yahoo Finance
Phenylketonuria Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | PTC Therapeutics, Homology Medicine, Synlogic, BioMarin Pharma - Barchart.com
BC consulted U.S. Batten disease experts who had links to drug company - Vancouver Sun
Solid Earnings Reflect BioMarin Pharmaceutical's (NASDAQ:BMRN) Strength As A Business - Yahoo Finance
Can Traders Expect Breakout From BioMarin Pharmaceutical Inc. This WeekJuly 2025 Setups & Stock Timing and Entry Methods - beatles.ru
BioMarin Announces Resignation of Chief Accounting Officer - The Globe and Mail
Skeletal Dysplasia Market Growth Analysis 2025-2030 - GlobeNewswire
Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance
Refocused, deal-hungry drugmaker BioMarin pushes toward $4 billion revenue target - The Business Journals
Blair William & Co. IL Cuts Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
PNC Financial Services Group Inc. Boosts Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
Risk vs reward if holding onto BioMarin Pharmaceutical Inc.Market Ready Picks with Technical Support - Newser
Using portfolio simulators with BioMarin Pharmaceutical Inc. includedFree Capital Protection Trading Strategies - Newser
What does recent volatility data suggest for BioMarin Pharmaceutical Inc.Machine Learning Stock Movement Detector - Newser
Will BioMarin Pharmaceutical Inc. Benefit From Broader Market BounceTrade Timing Strategy With Technical Data Explained - beatles.ru
Using economic indicators to assess BioMarin Pharmaceutical Inc. potentialFree Secure Return Focused Investment Plan - Newser
The Top 12 Companies Hiring in Biopharma Now - BioSpace
One Healthcare Stock to Watch: BioMarin Pharmaceutical (BMRN) - AInvest
Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Positive Earnings Growth Hasn't Been Enough to Get BioMarin Pharmaceutical (NASDAQ:BMRN) Shareholders a Favorable Return Over the Last Five Years - 富途牛牛
BioMarin Pharmaceutical Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2025 Earnings Call Transcript - Insider Monkey
BioMarin Pharmaceutical (BMRN) Receives a Buy from Stifel Nicolaus - The Globe and Mail
Biomarin Pharmaceutical shares rise 2.68% premarket after UBS raised its price target to $114. - AInvest
BioMarin Pharmaceutical Inc. Reports Strong Q2 2025 Results - The Globe and Mail
Backtesting results for BioMarin Pharmaceutical Inc. trading strategiesFree Daily Momentum Screener With Alerts - Newser
BioMarin’s Earnings Call: Growth Amid Challenges - TipRanks
BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401 (NASDAQ:BMRN) - Seeking Alpha
Research Alert: CFRA Keeps Buy View On Shares Of Biomarin Pharmaceutical Inc. - 富途牛牛
BIOMARIN PHARMACEUTICAL INC SEC 10-Q Report - TradingView
BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030 - inkl
BioMarin stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com
BMRN Makes Bullish Cross Above Critical Moving Average - Nasdaq
BioMarin touts promising early result for potential Voxzogo successor - Fierce Pharma
UBS Adjusts Price Target on BioMarin Pharmaceutical to $114 From $113, Maintains Buy Rating - MarketScreener
BioMarin Axes Pre-Clinical PKU Drug, Citing Underwhelming Immunogenicity - BioSpace
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View - Yahoo Finance
Morgan Stanley Raises Price Target on BioMarin Pharmaceutical to $104 From $96, Keeps Overweight Rating - MarketScreener
BioMarin raises 2025 full-year guidance with $3.125B revenue target and advances BMN 333 - MSN
BioMarin: Q2 Earnings Snapshot - New Haven Register
1.55%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):